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Abstract
Human Immunodeficiency Virus-1 (HIV-1)-associated neurocognitive disorder (HAND) is likely neuroinflammatory in origin,
believed to be triggered by inflammatory and oxidative stress responses to cytokines and HIV protein gene products such
as the HIV transactivator of transcription (Tat). Here we demonstrate increased messenger RNA for nuclear factor-kappa B
(NF-kB) family member, transcription factor RelB, in the brain of doxycycline-induced Tat transgenic mice, and increased
RelB synthesis in Tat-exposed microglial cells. Since genetic ablation of RelB in mice leads to multi-organ inflammation, we
hypothesized that Tat-induced, newly synthesized RelB inhibits cytokine production by microglial cells, possibly through the
formation of transcriptionally inactive RelB/RelA complexes. Indeed, tumor necrosis factor-alpha (TNFa) production in
monocytes isolated from RelB deficient mice was significantly higher than in monocytes isolated from RelB expressing
controls. Moreover, RelB overexpression in microglial cells inhibited Tat-induced TNFa synthesis in a manner that involved
transcriptional repression of the TNFa promoter, and increased phosphorylation of RelA at serine 276, a prerequisite for
increased RelB/RelA protein interactions. The Rel-homology-domain within RelB was necessary for this interaction.
Overexpression of RelA itself, in turn, significantly increased TNFa promoter activity, an effect that was completely blocked
by RelB overexpression. We conclude that RelB regulates TNFa cytokine synthesis by competitive interference binding with
RelA, which leads to downregulation of TNFa production. Moreover, because Tat activates both RelB and TNFa in microglia,
and because Tat induces inflammatory TNFa synthesis via NF-kB, we posit that RelB serves as a cryoprotective, anti-
inflammatory, counter-regulatory mechanism for pathogenic NF-kB activation. These findings identify a novel regulatory
pathway for controlling HIV-induced microglial activation and cytokine production that may have important therapeutic
implications for the management of HAND.
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Introduction
Human Immunodeficiency Virus-1 (HIV-1) enters the central
nervous system (CNS) early after infection, and in many cases may
ultimately result in HIV-1 associated neurologic disease (HAND)
[1]. HAND can include neurocognitive impairments, motor
deficits, or dementias [2], and continues to be a significant source
of morbidity despite efficacious reduction of viral load by
comprehensive anti-retroviral therapy (cART) [3–10]. Tradition-
ally, onset of HAND correlated with CNS viral load, and was
principally subcortical in origin, with neuropathology including
multinucleated giant cells, reactive astrocytosis, myelin pallor,
reduced dendritic complexity and synaptic density and neuronal
loss [11–16]. Recent neuropathologic reports of severe white
matter damage (i.e. leukoencephalopathy) in patients with HIV-1
infection and on cART [17–23], including significant frontostriatal
and prefrontal cortex involvement in HAND [24–27], suggest that
additional patterns of primary brain disease are emerging, either
due to alterations in host cell signaling, or as yet unexplained
interactions between virus, vulnerable populations of neural cells,
and cART [6,28].
The pathogenesis of HAND likely arises from a toxic milieu of
secretory neurotoxins released from HIV-1 infected, brain-resident
mononuclear phagocytes and glia, and oxidative stress, which
together adversely affect neuronal function. HIV productively
infects microglia and perivascular macrophages, the resident
phagocytes of the CNS, but does not infect neurons. This suggests
that the neuropathology caused by HIV is indirect. Accordingly,
neurologic deficits in HAND are more closely correlated with the
presence of activated macrophages and microglia than with the
amount of neuronal apoptosis or viral RNA [29–32]. Soluble viral
proteins such as Tat and the glycoprotein gp120 can be released
from infected microglia and macrophages [33]. Tat protein has
been detected in blood plasma, serum, and cerebral spinal fluid
(CSF) from HIV+ individuals, at levels ranging from 1–40 ng/ml
[34,35], thus local extracellular concentrations in the CNS may be
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[36]. Tat also interacts with and activates neighboring, uninfected
cells including microglia, astrocytes and neurons. Both infected
and activated microglia and astrocytes produce the pro-inflam-
matory cytokines tumor necrosis factor-alpha (TNFa) and
interleukin-1 beta (IL-1b), which further activate neighboring
cells. Infected and activated cells also produce chemokines such
as monocyte chemotactic protein-1 (MCP-1), attracting more
inflammatory monocytes and macrophages [37–39]. Thus, circu-
lating Tat has a high propensity to trigger this vicious cycle,
leading to neurologic deficits [34].
HIV-1 Tat is necessary for viral replication and activates the
nuclear factor-kappa B (NF-kB) signal transduction pathway in
cells of the CNS [40,41]. Cytokine and chemokine gene expression
in microglia, in turn, is also NF-kB dependent [41]. The NF-kB
family of transcription factors is intricately involved in both innate
and adaptive immune responses as well as in inflammation. In
mammalian cells, there are five NF-kB family members including
RelA (p65), RelB, cRel, p52 (with its precursor p100), and p50
(with its precursor p105). Homo- and hetero-dimeric combinations
of the five NF-kB proteins activate transcription of NF-kB target
genes. In resting cells, NF-kB dimers are retained in the cytoplasm
through their inhibitory interaction with the inhibitor of kappa B
(IkB) molecules [42]. Signals leading to activation of the NF-kB
pathway include the pro-inflammatory cytokines TNFa and IL-1b
[43]. Initiation of the NF-kB pathway is characterized by signal-
induced activation of the inhibitory kB kinase (IKK) complex.
IKK then phosphorylates IkBa leading to its subsequent
ubiquitination and proteolytic degradation [44]. Degradation of
IkBa frees NF-kB dimers to move to the nucleus, where they can
then activate transcription. We, and others, have demonstrated
that Tat-induced production of cytokines (e.g. TNFa) by microglia
involves activation of the NF-kB pathway, as evidenced by the
rapid degradation of IkBa in Tat treated microglial cells [41,45].
Indeed, overexpression of IkBa S32/36A, which is resistant to
proteasomal degradation, blocks Tat-induced TNFa synthesis in
microglial cells, thereby suggesting that Tat-induced TNFa
synthesis is NF-kB dependent [45].
Here we show that Tat treatment of microglial cells induces de
novo synthesis of RelB. The NF-kB family member RelB has many
distinguishing features compared to the other NF-kB proteins,
such as its unique amino-terminal leucine zipper motif [46]. RelB
also preferentially interacts with p100 rather than the usual NF-kB
inhibitory molecules (e.g. IkBa) [47,48]. RelB has lower relative
DNA binding activity at prototypical response elements, and can
both activate and inhibit transcription of target genes [49,50].
Specific nuclear DNA kB binding sites are efficiently recognized
by RelB/p52 DNA heterodimers, allowing for transcription of
certain kB-regulated target genes [49,51]. RelB also forms inactive
complexes with RelA [52–55]. In addition, studies in RelB
2/2
mice have demonstrated impaired cellular immunity and devel-
opment of multi-organ inflammation that involves activation of
myeloid cells [56,57]. RelB has also been shown to be inhibitory to
the TNFa promoter in fibroblasts [58,59]. Together these results
strongly suggest that RelB has anti-inflammatory and cytokine-
regulating properties. Herein we investigate these anti-inflamma-
tory properties of RelB in the context of HIV-induced neuro-
inflammation.
Initial experiments in transgenic mice expressing Tat under a
doxycycline (Dox)-inducible glial fibrillary acidic protein (GFAP)
promoter demonstrated increased RelB message in the brains of
Dox-induced mice, confirming that Tat increases RelB in vivo.
Furthermore, Tat also enhanced TNFa release from monocytes
isolated from RelB
2/2 mice as compared to monocytes from wild-
type (WT) mice, which is in agreement with previous reports of
anti-inflammatory properties of RelB. Next, in vitro experiments
were conducted to determine the mechanisms of RelB inhibition
of TNFa release from microglial cells. These experiments
suggested that RelB binds RelA to inhibit RelA-dependent
activation of the TNFa promoter, and that this RelB/RelA
mechanism of interaction requires the entire RelB Rel Homology
Domain (RHD). Taken together, these results suggest that RelB
may regulate cytokine synthesis by counter-regulating NF-kB
activated pathways, a finding that has important therapeutic
implications for the management of HAND.
Methods
Reagents
Cycloheximide (CHX) and MG-132 were obtained from
BioMol International/Enzo Life Sciences (Plymouth Meeting,
PA, USA). CHX was used at concentrations of 10 and 25 mg/mL
and MG-132 was used at a concentration of 50mM. Viral protein
gp120 SF162 was obtained from Immunodiagnostics (Woburn,
MA, USA), and used at a concentration of 100nM. All other
chemicals and regents were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
HIV-1 Tat 1–72 was expressed in Sf9 insect cells using a
baculovirus system and was purified using Ni-NTA agarose
according to the BD BaculoGold 66His expression and
purification protocol (BD Biosciences, San Jose, CA, USA).
Briefly, the Tat 1–72 sequence (from HIV-1, YU-2 isolate) was
PCR amplified and cloned into XhoI and NcoI sites in the
pAcHLT-B baculovirus transfer vector. The recombinant plasmid
was confirmed by sequencing. This transfer vector was then co-
transfected into Sf9 cells along with BD BaculoGold linearized
baculovirus backbone DNA. Resultant virus stock was propagated
in Sf9 cells. Tat protein was then purified from lysates of infected
Sf9 cells using Ni-NTA agarose beads.
Importantly, the Tat produced in this fashion and used for these
studies was functionally indistinguishable from E. coli prepared
Tat 1–72, and caused similar microglial activation of NF-kB
related pathways as previously seen for E. coli Tat 1–72 (Text S1,
Figure S1). Therefore this Sf9 Tat, hereafter referred to as ‘‘Tat,’’
was used for these studies, allowing us to take advantage of this
more efficient protocol for producing HIV-1 Tat in the high yields
required for these studies.
Tat 1–101 (Immunodiagnostics,Woburn, MA, USA), Tat 1–72
(Sf9-Tat), Tat 1–72 (E. coli Tat; kind gift of Dr. A. Nath, Johns
Hopkins University, Baltimore, MD, USA), Tat C31S (Diatheva,
Fano, Italy), Tat D31–61 (obtained from Philip Ray, University
of Kentucky, Lexington, KY, USA) and Tat peptides (Tat 48–
72: G-R-K-K-R-R-Q-R-R-R-P-P-Q-D-S-Q-T-H-Q-S-S-L-S-K-
Q; GenScript, Piscataway, NJ, USA; Tat 46–60: S-Y-G-R-K-K-
R-R-Q-R-R-R-P-P-Q; and Tat 65–80: H-Q-V-S-L-S-K-Q-P-T-
S-Q-P-R-G-D; Intracel Corp., Cambridge, MA, USA) were used
at 100nM (,800 ng/ml) concentration unless otherwise described.
It should be noted that soluble Tat levels in HIV patient sera have
been measured up to 40 ng/mL [34,35]. It has also been shown
that Tat can interact with endogenous glycosaminoglycans and
heparin sulfates, thereby potentially lowering its measurable
concentration in vivo [60]. Therefore, it is likely that Tat
concentrations surrounding HIV-infected cells are much higher
[36]. In addition, Tat’s exceedingly strong affinity for other
proteins and glass/plastic, and its temperature susceptibility, make
it impossible to determine exactly what fraction of the Tat
‘‘starting dose’’ actually reaches the experimental specimen, thus
likely leading to underestimation of Tat functions in vitro [61].
Anti-Inflammatory Role of RelB
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11875Finally, Tat’s effects in vivo are likely to occur over long-term
exposures. Chronic, low dose, in vivo effects of any reagent are
often appropriately modeled in vitro, by proportionately higher
doses of that same reagent, over more acute time frames. For these
reasons, and in order to be consistent with previous experiments
from our laboratories, and others, we use 100nM Tat for these
experiments, which is at the lower end of the Tat dose range seen
with many comparable studies, and which many studies have
found to be an appropriate Tat dose by which to model Tat’s in
vivo effects in vitro.
Cell Cultures
Primary cultures. Human peripheral monocytes were
isolated from commercially obtained soft-spun buffy coats (New
York Blood Center, Long Island City, NY, USA) derived from
HIV-1 and hepatitis B virus-seronegative donors, using immuno-
magnetic isolation methods as described [62,63]. Briefly,
peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coats after centrifugation on a lymphoprep gradient (AXIS-
Shield, Oslo, Norway). Monocytes were then isolated by positive
selection with anti-CD14 MACS beads (Miltenyi Biotec, Bergisch
Gladbach, Germany; Auburn, CA, USA), and cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS),
and antibiotics for 18–24h before use. The monocyte cultures
used in our experiments were .95% pure as determined by
morphologic criteria.
Mouse monocytes were isolated from bone marrow derived
from age-matched C57BL/6 (RelB
+/+) or RelB
2/2 mice by
positive selection with mouse/human anti-CD11b MACS beads
(Miltenyi Biotec, Bergisch Gladbach, Germany; Auburn, CA,
USA). These cells were cultured in RPMI 1640 medium
supplemented with 10% FBS and antibiotics for 16h before use.
Human astrocytes were kindly supplied by Dr. Anuja Ghorpade
(University of North Texas Health Science Center, Fort Worth,
Texas, USA). Briefly, brain tissue was mechanically dissociated,
centrifuged, and resuspended in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% FBS and 16 penicil-
lin-streptomycin-glutamine for 7 days. Non-adherentmicroglia and
oligodendrocytes were removed by extensive agitation (260 rpm)
on a rotating platform. Cultures of astrocytes were .98% pure
as determined by immunocytochemical (ICC) staining for GFAP
(rabbit polyclonal antibody, Chemicon/Millipore, Billerica, MA,
USA).
Cell-lines: The murine microglial cell-line (BV-2) and human
embryonic kidney cell line (HEK 293) were obtained from Dr. R.
Donato (University of Perugia, Perugia, Italy) and American Type
Culture Collection (ATCC, Manassas, VA, USA) respectively.
These cells were maintained in DMEM containing 10% FBS,
2mM glutamine, and antibiotics, by standard procedures.
ELISA
TNFa levels were measured in culture supernatants (pre-cleared
by brief centrifugation) by using a mouse TNFa ELISA kit
(eBioscience, San Diego, CA, USA) according to the manufactur-
er’s instructions. This kit has a minimum sensitivity threshold of
8 pg/ml. Briefly, 50 ml of cell culture supernatant was incubated in
a 96-well plate pre-coated with a TNFa-specific monoclonal
antibody for 1.5h. After extensive washing, binding of TNFa was
detected by incubation with biotinylated antibodies, followed by
streptavidin-peroxidase; colorimetric enzyme assays were per-
formed to detect bound TNFa. Other cytokine levels were
measured using Bio-Plex Multi-Plex analysis for detecting a panel
of multiple cytokines from a single sample (Bio-Rad, Hercules,
CA, USA). Briefly, this technology uses multiple spectrally
identifiable polystyrene beads, each coated with a different anti-
cytokine antibody, followed by target, then secondary antibody
binding, to detect multiple cytokines from a single sample in
typical sandwich-assay fashion. This assay was utilized to measure
levels of IL-1b, IL-6, and MCP-1 in supernatant samples, as
previously described [64–66]. TNFa ELISA results were also
confirmed by this assay.
Electrophoretic Mobility Shift Assays
Nuclear extracts were prepared from BV-2 cells as previously
described [67]. Electrophoretic mobility shift assays (EMSAs) were
performed by incubating nuclear extracts with
32P-radiolabeled
high affinity, double-stranded DNA probe suspended in EMSA
reaction buffer (12mM HEPES, pH 7.9, 100mM NaCl, 0.25mM
EDTA, 1mM dithiothreitol, and 1mM phenylmethanesulfonyl
fluoride) at room temperature for 10 min, followed by resolution
of the protein-DNA complexes on native 4% polyacrylamide gels,
then autoradiography. The double stranded oligonucleotide
probes used in EMSA were as follows: (1) NF-kB: 59-CAACGG-
CAGGGGAATTCCCCTCTCCTT-39 and (2) OCT-1: 59-TG-
TCGAATGCAAATCACTAGAA-39. For antibody supershift
assays, 1 mg of antiserum recognizing each of the NF-kB subunits
(Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA) was
added to the EMSA reaction 10 min prior to electrophoresis.
Specificity and reactivity of the antibodies was confirmed as
described previously [68,69].
Plasmids
The luciferase reporter construct driven by NF-kB as well as the
RelA and cRel plasmids were obtained from Dr. S. C. Sun (MD
Anderson Cancer Center, University of Texas, Houston, TX,
USA). The plasmids expressing mouse RelB (mRelB) and
influenza hemagglutinin (HA)-tagged derivative of RelA (HA-
RelA) were obtained from Dr. Bernd Baumann (Ulm University,
Ulm, Germany). We PCR amplified the mRelB sequence from
this plasmid and inserted it into the pcDNA3.1-Myc/His(-)B
vector (Invitrogen, Carlsbad, CA, USA). The luciferase reporter
construct driven by the mouse TNFa (mTNFa) promoter was
obtained from Dr. Dmitry Kuprash (Engelhardt Institute of
Molecular Biology, Moscow, Russia).
Transient Transfections
HEK 293 cells were transfected with plasmid DNA using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were
seeded at 1.8610
5 cells/well in 24-well plates 18h prior to
transfection. Each transfection reaction contained a total of
0.85 mg plasmid DNA. After addition of the transfection mixture
to the cells, they were incubated at 37uC for 24h. BV-2 cells
were transfected with plasmid DNA using Lipofectamine LTX
(Invitrogen, Carlsbad, CA, USA) or Nucleofector (Amaxa/Lonza,
Basel, Switzerland; Walkersville, MD, USA). For Lipofectamine
transfections, cells were seeded at 1610
5 cells/well in 24-well
plates 18h prior to transfection, then transfected as for Lipofecta-
mine 2000 above. For nucleofection, 5610
6 cells were transfected
with 10 mg NF-kB luciferase plasmid DNA. Transfected cells were
plated at 5610
5 cells/well in a 24-well plate and incubated for 24h
prior to Tat treatment. Media was changed 4h after transfection
and again prior to treatment to reduce cell toxicity. To determine
nucleofection-based transfection efficiency, an aliquot of BV-2
cells was transfected with a GFP-expressing vector, pMax-GFP
(Amaxa/Lonza, Basel, Switzerland; Walkersville, MD, USA), and
24h after transfection, greater than 90% of BV-2 cells were GFP-
positive.
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A luciferase reporter plasmid containing NF-kB responsive
elements upstream of a firefly luciferase gene was transfected into
BV-2 cells using Nucleofector (Amaxa/Lonza, Basel, Switzerland;
Walkersville, MD, USA). 24h post-transfection, cells were either
left untreated or incubated for 8h with 100nM Tat. Cell lysates
were prepared using reporter lysis buffer (Promega Life Sciences,
Madison, WI, USA), and luciferase activity was measured. A
luciferase reporter plasmid with the mouse TNFa promoter region
upstream of a luciferase reporter was transfected into either HEK
293 cells using Lipofectamine (Invitrogen, Carlsbad, CA, USA) or
BV-2 cells using Nucleofector (Amaxa/Lonza, Basel, Switzerland;
Walkersville, MD, USA). 24h post-transfection, cell lysates were
prepared using reporter lysis buffer (Promega Life Sciences,
Madison, WI, USA), and luciferase activity was measured with a
Lumicount Microplate Luminometer (Packard Instrument Com-
pany, Meriden, CT; now PerkinElmer, Waltham, MA). In these
assays, total protein amount as determined by Bradford assay (Bio-
Rad, Hercules, CA, USA), was used to normalize the samples.
Immunoblotting assays
Following the indicated treatments, whole cell lysates were
prepared in ELB buffer (50mM HEPES (pH 7), 250mM NaCl,
0.1% Nonidet P-40, 5mM EDTA, 10mM NaF, 0.1mM Na3VO4,
50mM ZnCl2, supplemented with 0.1mM PMSF, 1mM DTT, and
a mixture of protease and phosphatase inhibitors). Cellular debris
was removed by high-speed centrifugation. Lysates were fraction-
ated on 7.5% SDS-PAGE gels and protein was electrophoretically
transferred to Hybond ECL nitrocellulose membrane (GE
Healthcare Bio-Sciences Corporation, Piscataway, NJ, USA).
The membranes were analyzed for immunoreactivity with
primary antibodies raised against RelB (1:1000), RelA (1:1000),
IkBa (1:1000), or a-Tubulin (1:1000; all from Santa Cruz
Biotechnologies Inc., Santa Cruz, CA, USA), RelA P-S276
(1:1000), p100/p52 (1:1000, Cell Signaling Technology, Danvers,
MA, USA), Actin (1:1000, Calbiochem/EMD Chemicals, Gibbs-
town, NJ, USA), or antiserum to HIV-1 Tat (1:3000; NIH AIDS
Research & Reference Reagent Program, Germantown, MD,
USA). Bound antibodies were detected by species-specific,
horseradish peroxidase (HRP)-conjugated secondary antibodies
(1:3000, GE Healthcare Bio-Sciences Corporation, Piscataway,
NJ, USA), followed by addition of ECL reagent (Pierce
Biotechnology/Thermo Fisher Scientific, Rockford, IL, USA)
and subsequent exposure to x-ray film. Equal loading and
uniformity of protein transfer to the nitrocellulose membrane
were verified by stripping and reprobing the membranes with
primary antibodies specific to a-Tubulin or Actin.
Tat transgenic mice and Real-Time RT-PCR analyses
Tat transgenic mice were kindly provided by Dr. Johnny He
(Indiana University School of Medicine, Indianapolis, IN, USA)
[70]. Briefly, 6-week old Tat transgenic mice were treated with
80 mg/kg of doxycycline in saline, injected intraperitoneally (IP)
once daily for 0, 3, or 14 days. There were 4 mice per group for
the 0 and 14 day groups, and 5 mice in the 3 day group. Mice
were euthanized via cervical dislocation and brain tissue was
immediately dissected at 4uC, flash frozen in isopentene, and
stored at 280uC. RNA was isolated from half of each brain using
the PureLink
TM Total RNA Purification System (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol.
Complementary DNA (cDNA) synthesis was performed using 2 mg
total RNA, oligo-dT primers, and the Superscript III first-strand
synthesis system (Invitrogen, Carlsbad, CA, USA). Gene-specific
primer sequences were as follows: 1) Tat primers: forward
59-GCATCCAGGGGATCAGCCTA-39, reverse 59-CTGATG-
AGCTCTTCGTCGCT-39; 2) RelB primers: forward 59-CC-
CCTACAATGCTGGCTCCCTGAA-39, reverse 59-CACGGC-
CCGCTCTCCTTGTTGATT-39; 3) TNFa primers: forward 59-
ACTCCAGAACATCTTGGAAATAGC-39, reverse 59-GCGG-
ATCATGCTTTCTGTGC-39; 4) RelA primers: forward 59-
TCAAGATCAATGGCTACACAGG-39, reverse 59-GCATTC-
AAGTCATAGTCCCCG-39; 5) GAPDH primers: forward 59-
TGATGACATCAAGAAGGTGGTGAA-39, reverse 59-TCCT-
TGGAGGCCATGTAGGCCAT-39. Real-time RT-PCR was
performed using iQ
TM SYBRH Green PCR Supermix (Bio-Rad,
Hercules, CA, USA) and 100nM gene-specific forward and reverse
primers in 20 mL total volume. After denaturation for 3 min. at
95uC, the PCR was run for 40 cycles of 95uC for 30 sec., primer-
specific melting temperature (Tm uC) for 1 min., and 72uC for
30 sec. using an iCycler instrument (Bio-Rad, Hercules, CA,
USA). GAPDH served as an internal control in these experiments.
All animal experiments were carried out in accordance with the
Animal Welfare Act and the National Institute of Health
guidelines. The animal protocol was approved by the University
Committee on Animal Resources of the University of Rochester
Medical Center. The facilities and programs of the Vivarium and
Division of Laboratory Animal Medicine of the School of
Medicine and Dentistry are fully accredited by the Association
for the Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) and are in compliance with state law,
federal statute and NIH policy.
Immunoprecipitation
Samples containing equal amounts of protein were pre-cleared
by incubation with 2 mg of normal rabbit serum and 20 mLo fa
50/50 protein A/G+ agarose beads solution (both from Santa
Cruz Biotechnologies Inc., Santa Cruz, CA, USA) at 4uCo na
rotator for 1h. After the pre-clear step, the beads were removed by
centrifugation and samples were transferred to tubes with specific
antibodies (2 mg per sample). Samples were incubated with the
antibodies at 4uC for 18h on a rotator. 30 mL of 50/50 protein A/
G+ agarose beads were added to the samples, then they were
incubated with rotation for an additional 2h at 4uC. The beads
were then washed extensively with ELB lysis buffer supplemented
with 0.1mM PMSF, 1mM DTT, and a mixture of protease and
phosphatase inhibitors, and then boiled for 5 minutes in 20 mLo f
Laemmli buffer. Immunocomplexes were separated using SDS-
PAGE (7.5%), transferred to a nitrocellulose membrane and
probed with the indicated antibodies.
Statistical analysis
Mean data values and the standard error of the mean (SEM)
were calculated for each variable. Data involving the analysis of
multiple sample groups were analyzed by one-way ANOVA
followed by Bonferroni’s test for multiple comparisons. A value of
p,0.05 was designated as statistically significant.
Results
Transgenic expression of Tat induces RelB synthesis in
mouse brain
Tat transgenic (Tat-Tg) mice are used as a model of HIV-
induced neurocognitive disorders, as they develop Tat-induced
behavioral changes and neurological abnormalities including
hunched posture, tremor, ataxia, slow motor movement, and
seizures [70]. In addition, these mice exhibit neuropathologies
including astrocytosis, degeneration of neuronal dendrites, neuro-
nal apoptosis, and increased infiltration of activated monocytes
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disease (HAND). These mice express a Dox-inducible Tat gene
driven by the GFAP promoter, which drives Tat protein
production by astrocytes in the CNS [70].
RelB was originally identified as a protein that controls
inflammation [56,57,59], leading us to hypothesize that RelB
may mediate Tat’s effects in models of HAND. Thus, we first used
quantitative real-time PCR (qRT-PCR) to determine whether Tat
altered RelB or RelA expression levels in the brains of the Tat-Tg
mice. Total RNA isolated from brain tissue of mice induced with
doxycycline for 0, 3, or 14 days was used to measure the abundance
of Tat, RelB, and RelA transcripts. As compared to non-induced
Tat-Tg mice (Day 0, Dox–), there was an approximately 20-fold
increase in Tat mRNA levels in 14 day Dox-treated animals
(Figure 1). Since Tat is known to activate TNFa production, in
order to confirm the activity of Tat, we also measured TNFa
synthesis in Dox-exposed mice. Our results revealed an increase in
TNFa mRNA in the brains of Dox-induced mice, validating the
functional activity of Tat in these animals (data not shown).
Consistent with these effects, we also observed a nearly 5-fold
increase in RelB mRNA levels by day 14 Dox treatment,
confirming that Tat also increased RelB expression (Figure 1).
Interestingly, under these conditions, RelA mRNA levels remained
unchanged, suggesting that the Tat-mediated increase in RelB was
not a generalized effect of Tat on NF-kB subunits (Figure 1). Since
total RNA was isolated from whole brain tissue, we could not
determine which cell type most contributed to this Tat-induced
increase in RelB message in this in vivo model. However, our further
experiments in BV-2 microglial cells, primary human monocytes,
and primary human astrocytes suggest that both microglia and
astrocytes contribute to this increase.
RelB inhibits TNFa and cytokine production triggered by
Tat treatment
Microglia are believed to be principal mediators of HAND-
associated neuropathology. Therefore, to explore the functional
role of Tat-RelB induction in microglia, we examined Tat’s ability
to stimulate TNFa synthesis in magnetically sorted CD11b
+
monocytic cells derived from the bone marrow of RelB deficient
(RelB
2/2) mice. We chose these cells to model microglia for three
reasons: (1) microglia originate from myeloid lineage precursors in
the bone marrow [71], (2) CD11b
+ bone marrow cells are sensitive
to Tat [72], and (3) highly homogeneous monocyte cultures can be
obtained from the bone marrow of genetically modified mice [73].
The vast majority of CD11b-positive cells (nearly 95% of the total
isolated population) were monocytes, as determined by morpho-
logic criteria. Using immunoblot analyses, we first verified that 8h
100 nM Tat treatment stimulated RelB synthesis in these murine
monocytes, and that RelB is indeed absent in RelB
2/2 derived
cells (Figure 2A). Again, following 8h 100 nM Tat treatment of
these cells, we also collected culture supernatants and measured
TNFa levels by ELISA. The results shown in Figure 2B reveal
enhanced production of TNFa in Tat-treated RelB
2/2 monocytes
as compared to their RelB
+/+ counterparts, strongly suggesting an
anti-inflammatory role for RelB. The Bio-Plex Multi-Plex cytokine
array assay was also used to measure additional inflammatory
cytokine and chemokine levels in these same culture supernatants.
Likewise, these results (Figure 2C) indicated enhanced production
of IL-1b, IL-6, and MCP-1 in Tat-treated RelB
2/2 monocytes
compared to Tat-treated RelB
+/+ cells, further supporting an anti-
inflammatory role for RelB in the context of HIV. TNFa levels, as
determined by ELISA above, were also validated using the Bio-
Plex cytokine array, with similar results (data not shown).
We performed additional complementary experiments to test
whether RelB overexpression in the microglial BV-2 cell line could
reverse Tat’s effects on TNFa synthesis. In contrast to cRel
overexpression, which had no effect on Tat-induced TNFa pro-
duction, RelB overexpression reduced Tat-induced TNFa release
from BV-2 cells as we anticipated (Figure 3), further confirming
the inhibitory properties of RelB.
Because RelB was over-expressed in these BV-2 cells, there is
the possibility that over-expressing high levels of exogenous RelB
could interfere with cells’ ability to respond to Tat. This is not
likely for two reasons: 1. cRel overexpression did not affect Tat’s
ability to induce TNFa production, and 2. Immunoblot analysis of
transfected RelB levels, compared to RelB levels stimulated by 8h
100nM Tat treatment, showed no significant differences, thus
suggesting that exogenous RelB levels resulting from transfection
were similar to inducible RelB levels (data not shown). Together
these data indicate that RelB’s ability to reduce TNFa production
in Tat-exposed cells results from a functional effect of RelB, and is
not due to overexpression of RelB interfering with cells’ ability to
respond to Tat.
Tat induces de novo synthesis of RelB
Next we examined the mechanisms by which RelB regulates
TNFa production through Tat. To do this we employed the easily
genetically manipulatable microglial BV-2 cell line. First, we
needed to confirm that the Tat-induced increases in RelB that we
observed in our in vivo models, also translated to this in vitro model.
Although activation of NF-kB involves cytosolic-nuclear redistri-
bution of RelA (a major component of NF-kB) rather than de novo
synthesis of this protein, NF-kB activation also positively regulates
expression of other NF-kB family members, including RelB
Figure 1. Transgenic expression of Tat induces RelB synthesis in mouse brain. 6-week old Tat-transgenic mice were induced with
doxycycline for the indicated periods of time. Total RNA was extracted from brain tissue, reverse transcribed using oligo-dT primers, and subjected to
Real-Time SYBR Green RT-PCR amplification. Fold induction of Tat, RelB and RelA mRNA species was normalized to GAPDH and presented as a
function of the expression level in D0 samples. Data represent mean 6 SEM of four replicates for D0 and D14 samples, and five replicates for D3
samples. Statistical significance (***, p,0.001 or *, p,0.05) is denoted as compared to D0 samples.
doi:10.1371/journal.pone.0011875.g001
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novo synthesis of RelB in our model systems. As shown in Figure 4A,
relatively low levels of RelB were detected in untreated BV-2 cells.
Within 4h, these levels were profoundly elevated by 100nM Tat
and remained higher for up to 24h of Tat exposure. Under these
conditions, Tubulin levels (protein loading control) were not
altered. Further immunoblot analyses revealed that the Tat-
induced increase in RelB expression resulted from enhanced RelB
synthesis, as this effect was blocked by pre-treatment with the
protein translation inhibitor Cycloheximide (CHX) (Figure 4B).
Consistently, the Tat-induced increase in RelB expression was also
blocked by pre-treatment of BV-2 cells with a proteasomal
inhibitor, MG-132, or an inhibitor of chymotrypsin-like serine
proteases, N-alpha-tosylphenylalanyl chloromethyl ketone (TPCK),
suggesting that activation of the NF-kB signaling pathway might be
crucial for this effect (Figure 4C). Furthermore, the increase in RelB
levels was found to be a specific effect of Tat, as RelB was not
increased by treatment with another HIV viral protein, gp120
(Figure 4D). However, gp120’s failure to induce RelB synthesis was
not due to failure of cellular activation by gp120, because, as
expected [76], gp120 was able to induce TNFa release from BV-2
cells (data not shown).
Since microglia are a monocyte-derived cell type, we also
examined RelB protein levels in primary human monocytes, to
further translational relevance to primary human disease models.
Analogous to the responses seen in BV-2 cells, treatment of primary
human monocytes with Tat also resulted in increased RelB
expression, albeit with delayed kinetics (Figure 4E), suggesting that
Tat-mediated synthesis of RelB occurs in non-dividing cells as well.
Active RelB is associated with NF-kB family member p52, which is
proteolytically cleaved from the inhibitor p100 [48]. As such,
further immunoblot analysis revealed increased p100 expression,
and its processing into p52 molecules, in Tat-exposed primary
human monocytes (Figure 4F), as well as in BV-2 cells (Figure 4G).
Furthermore, we observed that this newly synthesized RelB rapidly
relocates to the nucleus, and thus is functionally active (Figure 4H).
Astrocytes are the most abundant cell type in the brain, are non-
productively infected with HIV-1 and, similar to microglia, can be
activated by viral proteins such as Tat, thereby contributing to
HIV-induced neuroinflammation [77]. For these reasons, we also
measured RelB protein levels following Tat treatment of primary
human astrocytes. As shown in Figure 4I, by 8h of Tat treatment
there is increased RelB synthesis in astrocytes, while Tubulin levels
remain unchanged.
Figure 2. RelB inhibits Tat-induced TNFa and cytokine production in monocytes. A, Monocytes from RelB
+/+ or RelB
2/2 mice (3610
5)
treated with Tat (100nM) for 8h and subjected to immunoblot analysis with either RelB-specific (upper panel) or Actin-specific (lower panel)
antibodies, confirmed that Tat induced RelB in these cells. Data are representative of results from two separate experiments. B, Levels of TNFa in
culture supernatants from these cells were analyzed by ELISA, and C, Levels of IL-1b, IL-6, and MCP-1 were anlayzed by Multi-Plex cytokine array as
described in Results. Data is shown as mean 6 SEM of values derived from three replicates each from two combined experiments. Statistical
significance (p,0.001) is indicated (***), as compared with Tat treated RelB
+/+ cells.
doi:10.1371/journal.pone.0011875.g002
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but RelA increases TNFa synthesis
To better understand how RelB inhibits Tat-induced TNFa
production, we used a reporter gene assay. To do this, BV-2 cells
were transiently transfected with a TNFa-promoter luciferase
reporter plasmid, either alone or together with increasing amounts
of WT RelB plasmid. The total amount of DNA in each
transfection was kept constant by addition of an appropriate
amount of pcDNA3.1 empty vector plasmid. These results
revealed that basal TNFa promoter activity was blocked by
overexpression of RelB (Figure 5A). To compare the effects of
RelA overexpression on TNFa promoter activity, we performed
similar additional luciferase assays in which HEK 293 cells were
transfected with the TNFa-promoter luciferase reporter, together
with increasing amounts of either RelA or RelB. As shown in
Figure 5B, in contrast to RelB, overexpression of increasing
amounts of RelA led to dose-dependent activation of the TNFa
promoter. These latter studies utilized HEK 293 cells for their
high transfection yields, and their robust (and thus readily
detectable) increases in TNFa promotor activity with RelA
expression, thus allowing us to determine the effects of RelB
expression on RelA transcriptional activity.
RelB interaction with RelA inhibits upregulation of the
TNFa promoter by RelA
Previous reports have shown that RelB and RelA interact, and
that this interaction can lead to inhibition of either RelA-
dependent or RelB-dependent gene expression in multiple cell
types [52–55]. Based on these reports, first we examined the effect
of RelB overexpression on RelA-induced activation of the TNFa
promoter. Overexpression of RelA alone resulted in an approx-
imately 10-fold increase in TNFa promoter activation, an effect
that was completely blocked by expressing increasing amounts of
RelB (Figure 5C). Interestingly, consistent with Figure 3, overex-
pressing increasing amounts of cRel (relevant control), or b-
galactosidase (irrelevant control), did not significantly inhibit
RelA-dependent activation of the TNFa promoter (Figure 5D),
suggesting that RelB exerts a selective inhibitory effect on RelA
transcriptional activity.
Next, to determine whether RelB interacts with RelA to achieve
these effects, we tested whether Tat stimulates protein-protein
interactions between endogenous RelA and RelB in BV-2 cells.
After addition of Tat for either 4h or 8h, whole cell lysates of BV-2
cells were collected, and RelA protein complexes were captured
with a RelA-specific antibody using Protein A/G+ agarose beads.
The bound proteins were then visualized by immunobloting with a
RelB-specific antibody. By 4h of Tat treatment there was a
significant increase in RelB protein that was pulled down with the
RelA antibody, thus demonstrating that Tat treatment was
stimulating interactions between RelA and RelB in BV-2 cells
(Figure 6A, top panel). The blot was stripped and re-probed with a
RelA-specific antibody to confirm that approximately equivalent
amounts of RelA protein were pulled down in each sample
(Figure 6A, bottom panel). Comparative densitometric analysis of
these bands, normalized to the RelA IP/RelA IB bands (bottom
panel), informed us that Tat increased RelB/RelA interactions by
4-fold at both 4h and 8h (Figure 6A, bar graph).
It was previously reported that RelA phosphorylation at serine
276 is required for the interaction between RelB and RelA to
occur [53]. Accordingly, using an antibody that specifically
recognizes serine 276 phosphorylated RelA, we were able to
confirm that RelA is indeed phosphorylated at serine 276 in Tat-
treated BV-2 cells (Figure 6B, blots). Quantification of these blots
found a 20–40 fold increase in the phosphorylated form of RelA in
Tat treated BV-2 cells versus controls (Figure 6B, graphs).
Thus, we predicted that this Tat-induced interaction between
RelB and RelA would therefore inhibit Tat-induced, RelA-
mediated transcriptional activation of NF-kB pathways. Indeed,
using an NF-kB luciferase reporter plasmid in BV-2 cells, our
results confirmed that overexpression of RelB inhibits activation of
endogenous NF-kB induced by 8h 100 nM Tat treatment
(Figure 6C). Likewise, analogous to the results shown in
Figure 5C, we observed a dose-dependent inhibition of RelA-
mediated NF-kB luciferase transcription following overexpression
of RelB in BV-2 cells (Figure 6D).
The entire Rel Homology Domain of RelB is necessary for
the interaction with RelA
To clarify how RelB might interact with RelA to inhibit
activation of the TNFa promoter, sequential deletion mutants
within RelB were made. These RelB deletion mutants were
overexpressed in HEK 293 cells together with HA-tagged RelA.
Co-immunoprecipitation (co-IP) was then used to test for
interactions between these proteins. Parallel cultures were also
co-transfected with the TNFa-promoter luciferase reporter, to
determine which of these deletion mutated RelB derivatives failed
to block transcriptional activity of RelA, which would suggest an
inhibitory domain interaction with RelA. We first focused on the
amino terminal leucine zipper domain of RelB, because this
domain is unique to RelB among the NF-kB family members.
Leucine zipper domains are also known to be involved with
protein-protein interactions [46]. However, amino terminal
truncation mutants of RelB, including deletion of the entire
leucine zipper domain, still interacted with HA-RelA as shown by
co-IP, and these mutants also inhibited RelA activity equally well
(Figure 7A), suggesting that this region was not responsible for the
transcription-inhibiting interactions of RelB on RelA.
We then introduced sequential deletions within the Rel
Homology Domain (RHD) of RelB (Figure 7B). The RHD
of NF-kB proteins is known to be responsible for homo- and
Figure 3. RelB inhibits Tat-induced TNFa production in BV-2
microglia. BV-2 cells (5610
6) were transiently transfected with either
empty vector (pcDNA3.1-Myc/His-B), cRel, or RelB (10 mg), using
Nucleofector (Amaxa/Lonza), and treated with Tat (100nM) for the
indicated periods of time. TNFa release was measured by ELISA and
normalized to total cellular protein content in the culture wells. Results
are shown as mean 6 SEM of values derived from two replicates from
one representative experiment; two total experiments were performed.
Statistical significance (p,0.05) is indicated, as compared to empty
vector transfected cells (*).
doi:10.1371/journal.pone.0011875.g003
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PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11875Figure 4. Tat induces de novo synthesis of RelB. A, BV-2 cells (1.2610
5) were treated with Tat (100nM) for the indicated periods of time and
whole cell lysates were subjected to immunoblot analysis using either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel) antibodies. B, BV-
2 cells (1.2610
5) were treated with Tat alone or together with CHX as indicated for 4h. Whole cell lysates were subjected to immunoblot analysis
using either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel) antibodies. C, BV-2 cells (1.2610
5) were treated with Tat (100nM) alone or
together with MG-132 or TPCK both at a concentration of 50mM for the indicated periods of time. Whole cell lysates were subjected to immunoblot
analysis using a RelB-specific (upper panel) antibody. Levels of a nonspecific (n.s.) band (lower panel) are shown to indicate equal protein loading. D,
BV-2 cells (1.2610
5) were treated with gp120 (SF162, 100nM) for the indicated periods of time and whole cell lysates were subjected to immunoblot
analysis using either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel) antibodies. E, Primary human monocytes (2610
5) were treated with
Tat for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either RelB-specific (upper panel) or Actin-
specific (lower panel) antibodies. F, Primary human monocytes (2610
5) were treated with Tat for the indicated periods of time and whole cell lysates
were subjected to immunoblot analysis using either p100/p52-specific (upper panel) or Actin-specific (lower panel) antibodies. G, BV-2 cells (1.2610
5)
were treated with Tat for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either p100/p52-specific
(upper panel)o ra-Tubulin-specific (lower panel) antibodies. H, BV-2 cells (1.2610
5) were treated with Tat as indicated and cytosolic (labeled ‘‘C’’) and
nuclear (labeled ‘‘N’’) extracts were subjected to immunoblot analysis with either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel)
antibodies. I, Primary human astrocytes (4610
4) were plated 72h prior to treatment. These cells were treated with Tat as indicated and whole cell
lysates were subjected to immunoblot analysis using either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel) antibodies.
doi:10.1371/journal.pone.0011875.g004
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these sequential RelB RHD deletion mutants, as well as deletion of
the proximal nuclear localization signal located between residues
388–392 within RelB, still formed complexes with RelA and
inhibited its activity (Figure 7B). However, the ability of RelB to
interact with RelA, and to inhibit RelA-dependent activation of the
TNFa promoter, was lost following deletion of the entire RHD
(D52–402, Figure 7B;akaDRHD RelB,Figures 7Cand7D).Thisis
reported in tabular format in Figure 7B (bottom line), with
Figures 7C and 7D illustrating the failure of DRHD RelB to
interact with RelA (7C), and to inhibit RelA activation of TNFa
transcriptional activity (7D),respectively. Theseresults indicate that
the entire RHD of RelB is necessary for its interaction with RelA.
Amino terminal region of Tat is necessary for RelB
induction in microglia
The HIV-1 protein Tat is a multi-functional protein. Residues
1–72 are encoded by the first exon and residues 73–101 are
encoded by a second exon [79]. It is released from infected
microglia, macrophage and astrocytes in the CNS [80]. Despite its
small size, Tat has multiple domains conferring different
functional effects. For example, amino acids 1–48 contain
protine-rich as well as cysteine-rich regions that represent a
minimal activation domain of HIV-1 Tat required for activation of
the HIV-1 promoter region, known as the long terminal repeat
(LTR). The basic domain 49–72 contains an RKKRRQRRR
motif, which confers the RNA binding activity of Tat and is also
important for cellular uptake and nuclear distribution of this
protein [81], while amino acids 65–80 of Tat include the RGD
motif that is involved in binding to cellular integrins [81,82].
Sequences from 22–37, a cysteine-rich domain, bind with divalent
cations like zinc and cadmium, thereby inducing the dimerization
and subsequent inactivation of Tat [83]. Mutations in the region
1–21 are tolerant to changes without the loss of biologic activity; in
contrast, changes in amino acids 25–40 are generally deleterious
for transactivation. Moreover, substitution at cysteine residues 22,
25, 27 and 37 alters transactivation of the HIV LTR [81]. The
cysteine residue at position 31 is critical for binding to the NMDA
receptor on neurons and mediating neurotoxicity [84]. Chemo-
tactic properties have also been attributed to this residue [85].
Here we have tested various length Tat proteins to determine
which domains are necessary for induction of RelB synthesis in
microglial cells. A diagram depicting the Tat peptides we used to
treat BV-2 cells is shown in Figure 8A.
Figure 5. Opposing effects of RelA and RelB on TNFa promoter activity. A, BV-2 cells (1.2610
5) were transiently transfected with 0.25 mgo f
plasmid DNA containing a luciferase reporter gene under transcriptional control of the mouse TNFa promoter region in the absence or presence of
increasing amounts of a RelB-encoding plasmid. 24h later cells were lysed and luciferase activity was determined. Total protein amount, as
determined by Bradford assay was used to normalize the samples. Data are presented as fold change compared to cells transfected with the
luciferase reporter alone. ***, p,0.001, and **, p,0.01 as compared to cells transfected with the luciferase reporter alone. B, HEK 293 cells (1.8610
5)
were transiently transfected with the mouse TNFa promoter-luciferase reporter plasmid along with increasing amounts of a plasmid for RelA or RelB.
The luciferase (i.e. TNFa promoter) activity in whole cell lysates was determined 24h post-transfection. Samples were subjected to immunoblot
analysis using either RelA or RelB-specific antibodies to determine the expressed level of RelA and RelB protein. ***, p,0.001 as compared to cells
transfected with the luciferase reporter alone. C, HEK 293 cells (1.8610
5) were transiently transfected with the mouse TNFa promoter-luciferase
reporter plasmid along with a plasmid for RelA in the absence or presence of increasing amounts of RelB-encoding plasmid. The luciferase activity in
whole cell lysates was determined 24h post-transfection. Samples were subjected to immunoblot analysis using either RelA or RelB-specific
antibodies to determine the expressed level of RelA and RelB protein. ***, p,0.001 as compared to cells transfected with the luciferase reporter
alone. D, HEK 293 cells (1.8610
5) were transiently transfected with the mouse TNFa promoter-luciferase reporter along with a plasmid for RelA in the
absence or presence of increasing amounts of cRel or b-galactosidase-encoding plasmid. Luciferase activity in whole cell lysates was determined 24h
post-transfection.
doi:10.1371/journal.pone.0011875.g005
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72 both induced an approximately 10–12-fold increase in RelB
levels by 8h of treatment in BV-2 cells, suggesting that the first
exon of Tat is required for RelB induction in microglia.
Similarly, Tat C31S and Tat D31–61 treatments led to a 10–
12-fold increase in RelB synthesis, suggesting that the altered
residues in these variants are dispensible. In contrast, Tat 48–
72, 46–60 and 65–80 did not induce RelB synthesis in BV-2
cells, indicating that the basic motif within Tat is not sufficient
to stimulate RelB production. Our results suggest that the
amino terminal region, consisting of amino acids 1–30 of
Tat, is critical for Tat-dependent RelB activation in microglia.
It may also be that multiple domains within the first exon of
Tat are necessary for the Tat-induced increase in RelB
synthesis. This possibility is currently under investigation in
our laboratory.
Discussion
Neuroinflammatory responses and monocyte/macrophage
CNS infiltration appear critical to the development of HAND
even with cART, and are not significantly reduced by cART
[86,87], thus, this remains a critical area of investigation in the
pursuit of adjunctive therapies for reducing the impact of HIV on
the nervous system. We, and colleagues, have previously shown
that TNFa released from HIV infected or activated monocytes/
microglia is a major contributor to HIV-induced neuroinflamma-
tion that leads to neuron damage and cognitive impairment
[45,88–94]. Moreover, many key aspects of TNFa signaling occur
via NF-kB [95,96], and NF-kB signaling is likely to be a key
mediator of TNFa’s neurotoxic actions in HAND, particularly in
regards to activation and HIV infection of brain macrophages and
microglia [97,98]. Accordingly, TNFa and NF-kB signal trans-
Figure 6. RelB inhibits NF-kB activation via physical interaction with RelA. A, BV-2 cells (8610
5) were treated with Tat (100nM) for the
indicated periods of time. Whole cell lysates were subjected to immunoprecipitation using a RelA-specific antibody and Protein A/G+ agarose beads.
Immunocomplexes were separated by 7.5% SDS-PAGE and blotted onto nitrocellulose membrane and subjected to immunoblot analysis with
antibodies specific for RelB or RelA. The plot below the bands represents densitometry values for each band, normalized as a ratio of RelA(IP)/RelB(IB)
(i.e. top bands): RelA(IP)/RelA(IB) (i.e. bottom bands), to indicate the increase in RelB/RelA interactions at each time point. B, BV-2 cells (1.2610
5) were
treated with Tat (100nM) for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either RelA-specific
(upper panel), RelA phospho-serine 276-specific (center panel)o ra-Tubulin-specific (lower panel) antibodies. Protein levels were quantified using
ImageJ software (bottom graphs). The results of a single representative experiment are shown. C, BV-2 cells (5610
6) were transiently transfected
using Nucleofector (Amaxa/Lonza) with an NF-kB-dependent luciferase reporter plasmid either alone or together with a RelB-encoding plasmid. 16h
post-transfection cells were either left untreated or were treated with Tat (100nM) for 8h. Luciferase activity in whole cell lysates was determined.
Results are shown as mean 6 SEM of values derived from three replicates from one representative experiment; two total experiments were
performed. Statistical significance (p,0.001) is indicated (***). D, BV-2 cells (1.5610
5) were transiently transfected using Lipofectamine (Invitrogen)
with the NF-kB-luciferase reporter plasmid together with a plasmid for RelA in the absence or presence of increasing amounts of RelB-encoding
plasmid. The luciferase activity in whole cell lysates was determined 18h post-transfection. Results are shown as mean 6 SEM of values derived from
two replicates from one representative experiment; two total experiments were performed.
doi:10.1371/journal.pone.0011875.g006
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other viral proteins or mediators are thought to perpetuate HIV-
induced nervous system damage [99–108]. RelB, in turn, is an NF-
kB family molecule with known anti-inflammatory properties and
modulatory roles in NF-kB signal transduction. While Rel family
members have previously been implicated as possible mediators of
HIV- and Tat-dependent transcription [100], the precise mech-
anisms of this regulation remain unclear. Furthermore, RelB
modulation of cytokine and TNFa activation in microglial cells is
an area that may have significant importance for understanding
HAND pathology, yet until now has remained unexplored.
Herein we describe a novel inhibitory regulatory feedback loop
for reducing inflammatory responses in microglial cells, whereby
RelB protein-protein interactions with RelA inhibit RelA’s
transcriptional activity, to regulate NF-kB mediated cytokine
synthesis. Early reports indicated that RelB exclusively formed
heterodimers with p50 and p52. It was not until 2003 that
Marienfeld et. al reported an interaction between RelB and RelA
in multiple cell types [52]. RelB/RelA interactions may not have
been reported earlier because this complex might not bind well to
typical kB DNA binding elements, or the level of this complex
might be low compared to levels of other RelB complexes.
Figure 7. RelB Rel homology domain required for interaction with RelA and blockade of TNFa promoter activity. A, B, Diagrams show
representation of full length and deletion mutants of RelB used to determine the domains of RelB necessary for interaction with RelA. HEK 293 cells
(1.8610
5) were transiently transfected with either HA-tagged RelA or Myc-tagged RelB deletion mutants alone or in combination. Interaction was
determined by immunoprecipitation with Myc-specific antibody and Protein A/G+ agarose beads followed by immunoblot analysis with HA-specific
or Myc-specific antibodies. Interacting (+) and non-interacting (2) mutants are indicated. These RelB deletion mutants were also analyzed using the
TNFa promoter-luciferase reporter plasmid co-transfected into HEK 293 cells together with a plasmid for RelA in the absence or presence of
increasing amounts of RelB-encoding plasmid (WT or deletion mutants). Inhibition of RelA activation of the TNFa promoter is indicated (+/2). C, HEK
293 cells (1.8610
5) were transiently transfected with either HA-tagged RelA or Myc-tagged RelB D52–402 alone or in combination. Interaction was
determined by immunoprecipitation with Myc-specific antibody and Protein A/G+ agarose beads followed by immunoblot analysis with HA-specific
or Myc-specific antibodies. D, RelB D52–402 was also analyzed using the TNFa promoter-luciferase reporter plasmid co-transfected into HEK 293 cells
along with a plasmid for RelA in the absence or presence of increasing amounts of RelB D52–402-encoding plasmid. Statistical significance (p,0.001)
as compared to cells transfected with 0.1 mg WT RelB+RelA is indicated (***).
doi:10.1371/journal.pone.0011875.g007
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since been described in fibroblasts, dendritic cells, and THP-1
human monocyte cells [53–55].
Here we describe for the first time, direct inhibition of RelA-
dependent TNFa transcription by RelB in microglia, as a result of
RelB/RelA protein interactions. These findings are supported by
other work showing that LPS stimulation of RelB
2/2 fibroblasts
resulted in enhanced production of cytokines IL-1a, IL-1b, and
TNFa [58], and chemokines RANTES, MIP-1a, MIP-1b, MIP-2,
IP-10, JE/MCP-1, and KC/CINC [59]. In addition, another
study demonstrated that RelB expression correlated with IL-1b
repression in human monocyte THP-1 cells [55]. All these findings
likely have parallels with our findings herein, that RelB deficiency
leads to enhanced Tat-induced TNFa transcriptional activity, and
that RelB expression reduces this activity. On the other hand, and
in stark contrast, macrophages isolated from RelB
2/2 deficient
mice demonstrated impaired TNFa production in response to LPS
[57]. This study emphasizes that the exact consequences of
RelB regulation of TNFa may be specifically dependent upon
both the nature of the inflammatory insult, and upon the cell type
affected – as is commonly the case with immunomodulatory signal
transduction – thus highlighting the need for further studies of
these effects in other cell types relevant to HIV neurologic disease,
as we seek to further validate RelB as a potential therapeutic target
in HAND.
Finally, since TNFa can be a downstream modulator of Tat’s
effects [104], it is possible that TNFa, rather than Tat directly, is
the molecule responsible for inducing the RelA serine 276
phosphorylation that we observed in Tat-treated microglia. In
addition, it is likely that either Tat- or TNFa-induced activation of
NF-kB could also explain the increase in RelB, as RelB is known
to be induced by NF-kB, and blockade of NF-kB signaling
mechanisms with inhibitors MG-132 or TPCK inhibited the
increase in microglial RelB. While additional studies are needed to
further clarify these mechanisms, these possibilities do not conflict
with our supposition that the RelB/RelA interactions shown here
in Tat-treated microglial cells, represent a novel negative
regulatory feedback loop for the resolution of inflammation in
microglial cells, specifically by inhibiting RelA activation of pro-
inflammatory cytokines such as TNFa. This mechanism may
explain why more severe cognitive impairment is not present until
late in the course of HIV infection, with HIV-induced inflamma-
tory mediators provoking a constant ‘‘yin and yang’’ between
inflammation and resolution of inflammation in the CNS.
Uncovering new mechanisms involved in resolving CNS
inflammation has many potential benefits both in terms of
reducing inflammation-induced neuronal damage, and also
possibly limiting viral spread by reducing inflammation-induced
influx of monocytes into the CNS. Moreover, TNFa and related
cytokines have pleiotropic neuromodulatory, neurotoxic, and even
neuroprotective functions [109], and are implicated in a wide
range of CNS and peripheral disease states. Thus, identifying this
novel negative regulatory feedback loop involving RelB could be
particularly useful as an adjunctive therapeutic approach for
HAND, peripheral HIV infection, or even other neurologic or
immune diseases, since overexpression of RelB in microglial cells
does not completely block Tat-induced release of TNFa, which
would negatively impact TNFa’s other endogenous functions. In
total, these results described herein represent an important first-
step toward furthering our understanding of RelB as a potentially
important mediator of wide-ranging disease states.
Supporting Information
Text S1 Recombinant Tat produced in eukaryotic cells activates
microglia.
Found at: doi:10.1371/journal.pone.0011875.s001 (0.04 MB
DOC)
Figure S1 Recombinant Tat produced in eukaryotic cells
activates microglia. A, HIV-1 Tat 1–72 protein was purified from
recombinant baculovirus infected Sf9 insect cell cultures. Increas-
ing volumes of the eluted protein were subjected to immunoblot
analysis using antiserum to HIV-1 Tat. The Tat-specific band is
indicated. B, BV-2 cells (1.2610
5) were treated with Sf9-Tat (1–72,
100nM), or E.Coli-Tat (1–72, 100nM, from Dr. A. Nath) for 8h
and levels of TNFa in the culture supernatant quantified by
ELISA. Data correspond to mean 6 SEM of three replicates, from
a single representative experiment; the experiment was performed
twice. C, BV-2 cells (1.2610
5) were treated with Sf9-Tat (100nM)
for the indicated periods of time and whole cell lysates were
subjected to immunoblot analysis using either IkBa-specific (upper
panel) or a-Tubulin-specific (lower panel) antibodies. Data are
representative of results from two separate experiments. D, For the
EMSA, 4 mL of nuclear protein extract from BV-2 cells treated
Figure 8. Amino terminal region of Tat is necessary for RelB
induction in microglia. A, Diagram shows a representation of full
length, mutated and truncated Tat proteins and peptides used in these
experiments. B, BV-2 cells (1.2610
5) were treated with Tat (100nM) for
8h and whole cell lysates were subjected to immunoblot analysis using
either RelB-specific (upper panel)o ra-Tubulin-specific (lower panel)
antibodies. These results indicate that standard Tat 1–101, Tat 1–72, Tat
C31S, and Tat D31–61 all activated RelB, whereas Tat peptides 48–72,
46–60 and 65–80 did not. C, Densitometry quantification of immuno-
blots shown in B. RelB levels were normalized to Tubulin levels and fold
change compared to non-treated (NT) was calculated.
doi:10.1371/journal.pone.0011875.g008
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together with a
32P-labeled palindromic NF-kB oligonucleotide.
The samples were separated on a native polyacrylamide gel that
was then fixed, dried, and exposed to x-ray film. The two major
DNA binding complexes consisting of NF-kB family members, as
labeled, were identified by antibody supershift analysis.
Found at: doi:10.1371/journal.pone.0011875.s002 (0.67 MB TIF)
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